B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2015 Aug 21

PMID 26290110

Citations 7

Authors

Md Yuzaiful Md Yusof

Edward M Vital

Maya H Buch

Affiliations

Soon will be listed here.

Abstract

The development of B cell-targeted biologics represents a major advance in the treatment of autoimmune rheumatic diseases. As with other immunosuppressive agents, risk of infection is a key clinical concern. This review summarises safety data from 15 years of experience of rituximab in autoimmune diseases with a particular focus on opportunistic infection and class-specific complications and infection risk. Rarely, cases of progressive multifocal leucoencephalopathy in rituximab-treated patients (5/100 000) have accumulated over time although no proven causal association has yet been shown. With repeat cycles of therapy, hypogammaglobulinaemia has been observed in a larger proportion of patients and is associated with increased risk of serious infections. The infection profile of the newer B cell-targeted agent, belimumab, in patients with active systemic lupus erythematosus is also discussed. Data from registries are needed to extend insights further and also to evaluate for any impact with the difference in mode of action of belimumab and infection risk in this population.

Citing Articles

A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments.

Gulig P, Swindle S, Fields M, Eisenman D Appl Biosaf. 2024; 29(4):186-206.

PMID: 39735407 PMC: 11669762. DOI: 10.1089/apb.2024.0002.

Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review/meta-analysis.

Gombolay G, Dutt M, Tyor W Ann Clin Transl Neurol. 2022; 9(8):1321-1331.

PMID: 35852423 PMC: 9349877. DOI: 10.1002/acn3.51628.

Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).

Nunez Cuadros E, Calzada-Hernandez J, Clemente D, Guillen Martin S, Silveira L, Lirola-Cruz M Eur J Pediatr. 2022; 181(6):2343-2354.

PMID: 35258699 PMC: 9110499. DOI: 10.1007/s00431-022-04418-7.

Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis.

Alamilla-Sanchez M, Alcala-Salgado M, Alonso-Bello C, Fonseca-Gonzalez G Int J Nephrol Renovasc Dis. 2021; 14:441-458.

PMID: 34924767 PMC: 8675090. DOI: 10.2147/IJNRD.S335371.

Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications.

Patterson S, Schmajuk G, Evans M, Aggarwal I, Izadi Z, Gianfrancesco M Jt Comm J Qual Patient Saf. 2019; 45(5):348-357.

PMID: 30686706 PMC: 7433663. DOI: 10.1016/j.jcjq.2018.12.003.

References

Vital E, Dass S, Buch M, Henshaw K, Pease C, Martin M . B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011; 63(10):3038-47. DOI: 10.1002/art.30466. View

Ginzler E, Wallace D, Merrill J, Furie R, Stohl W, Chatham W . Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2013; 41(2):300-9. DOI: 10.3899/jrheum.121368. View

Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I . The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011; 29(8):1643-8. DOI: 10.1016/j.vaccine.2010.12.072. View

Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D . Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2012; 72(2):308-10. DOI: 10.1136/annrheumdis-2012-202088. View

Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9):2368-79. DOI: 10.1002/art.38037. View

Ramos-Casals M, Soto M, Cuadrado M, Khamashta M . Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009; 18(9):767-76. DOI: 10.1177/0961203309106174. View

Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J . Rituximab administration and reactivation of HBV. Hepat Res Treat. 2010; 2010:182067. PMC: 3003947. DOI: 10.1155/2010/182067. View

Bingham 3rd C, Looney R, Deodhar A, Halsey N, Greenwald M, Codding C . Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2009; 62(1):64-74. DOI: 10.1002/art.25034. View

Diaz-Lagares C, Croca S, Sangle S, Vital E, Catapano F, Martinez-Berriotxoa A . Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2011; 11(5):357-64. DOI: 10.1016/j.autrev.2011.10.009. View

10.

van Vollenhoven R, Emery P, Bingham 3rd C, Keystone E, Fleischmann R, Furst D . Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2012; 72(9):1496-502. PMC: 3756452. DOI: 10.1136/annrheumdis-2012-201956. View

11.

Navarra S, Guzman R, Gallacher A, Hall S, Levy R, Jimenez R . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767):721-31. DOI: 10.1016/S0140-6736(10)61354-2. View

12.

Lin K, Lin J, Tseng W, Cheng T . Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect. 2012; 46(1):65-7. DOI: 10.1016/j.jmii.2011.12.020. View

13.

Grijalva C, Kaltenbach L, Arbogast P, Mitchel Jr E, Griffin M . Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford). 2009; 49(1):82-90. PMC: 2909794. DOI: 10.1093/rheumatology/kep325. View

14.

Lutt J, Pisculli M, Weinblatt M, Deodhar A, Winthrop K . Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol. 2008; 35(8):1683-5. View

15.

Besada E, Nossent J . Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?. Clin Rheumatol. 2013; 32(11):1677-81. DOI: 10.1007/s10067-013-2293-4. View

16.

Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006; 54(5):1390-400. DOI: 10.1002/art.21778. View

17.

Kourbeti I, Ziakas P, Mylonakis E . Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014; 58(12):1649-57. DOI: 10.1093/cid/ciu185. View

18.

Bongartz T, Orenstein R . Therapy: The risk of herpes zoster: another cost of anti-TNF therapy?. Nat Rev Rheumatol. 2009; 5(7):361-3. DOI: 10.1038/nrrheum.2009.120. View

19.

Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D . Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350(25):2572-81. DOI: 10.1056/NEJMoa032534. View

20.

Fredericks C, Kvam K, Bear J, Crabtree G, Josephson S . A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus. 2014; 23(7):711-3. DOI: 10.1177/0961203314524292. View